Company name
AlphaMol Science Ltd
Company profile
AlphaMol Science Ltd. is a clinical-stage biotech focused on first-in-class GPCR-targeted small molecules. Its lead MRGPRX2 antagonist is advancing for mast cell–driven diseases, while a GPR75 program targets obesity with strong preclinical efficacy. Powered by a proprietary GPCR-AI platform, AlphaMol integrates computational biology and translational science to deliver innovative therapeutics.
Date, time and room information
Tuesday, May 5, 13:45 - 14:00, room Montreal
Category
Clinical stage development company
Title of the presentation
Advancing first-in-class GPCR drug discovery into clinical trail via AI precision
Speaker information
| Name | Position | Institution |
|---|---|---|
| Shuguang Yuan | CEO | AlphaMol Science Ltd |
